Verastem (VSTM)
(Delayed Data from NSDQ)
$2.68 USD
-0.06 (-2.19%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $2.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 101 - 120 ( 267 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Strategic Shift to Focus on Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Copiktra Sales Picking up Steam; Higher $3.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Potential Path to Approval in Ovarian Cancer; Lung Results Await Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
New Strategy Bolstered by Strong Balance Sheet; Higher $2.75 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 24 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Promising Combination Results in New License Agreement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Promising Clinical Updates at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
First Steps on the Long Road to Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
New Management Outlines Copiktra Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
We are placing shares of VSTM Under Review, and transferring coverage to Jerry Isaacson, Ph.D. due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.